Last updated: Oct 16, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07594067 | 1 | TCR1188-ABC Cells in KRAS-mutated Cancers | KRAS mutant peptides -- T cell receptor (TCR) engineered T cells |
| NCT07715903 | 1 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | Proteasome -- proteasome inhibitor (carfilzomib) |
| NCT06293898 | 1 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | HER2 -- antibody-drug conjugate |
| NCT06467357 | 3 | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer | HER2 -- antibody-drug conjugate (Trastuzumab deruxtecan) + Rilvegostomig (unknown mechanism) + chemotherapy + PD-L1 inhibitor (Durvalumab) |
| NCT07766187 | 2 | Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma | PD-L1 -- immune checkpoint inhibitor (monoclonal antibody) |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 14 |
| Tianjin Medical University Cancer Institute and Hospital | 9 |
| Shanghai Zhongshan Hospital | 9 |
| Peking Union Medical College Hospital | 7 |
| West China Hospital | 5 |
Countries/regions with the most active trial sites for cholangiocarcinoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Dec 2026 | NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | KRAS mutant peptides -- T cell receptor (TCR) engineered T cells |
| Nov 2026 | NCT07738939 | IKS04 Regimen in Advanced Solid Tumors That Express CA242 | CA242 -- antibody-drug conjugate (ADC) |
| Oct 19, 2026 | NCT07715903 | Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy | Proteasome -- proteasome inhibitor (carfilzomib) |
| Sep 15, 2026 | NCT07632235 | A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma | COX-2 -- selective inhibition (NSAID); PD-1 -- immune checkpoint blockade (monoclonal antibody) |
| Sep 2026 | NCT07796997 | GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy | Glucocorticoid receptor -- anti-inflammatory and immunosuppressive effects (steroid hormone) |
| May 2026 | NCT07614061 | Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer | CD160 -- autologous antigen-specific T-cell therapy |
| Mar 27, 2026 | NCT07107750 | Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer | IRAK4 -- small molecule inhibitor (Emavusertib) + chemotherapy (Gemcitabine, Cisplatin) + PD-L1 -- immune checkpoint inhibitor (Durvalumab) |
| Mar 2, 2026 | NCT07641036 | Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer | HER2 + CEACAM5 -- dual-target chimeric antigen receptor natural killer cells (CAR-NK) |
You've seen the cholangiocarcinoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.